Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer

Fonseca, Francisco Paulo da; Lopes, Alberto; Junior, Wesley; Marquez, Obadias; Pereira, Raimunda N.

doi:10.1590/s1516-31801998000500003

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other studies have not found any statistically significant difference when comparing prostate adenocarcinoma in Whites and in Blacks (5). Similarly, in Brazil the majority of screening studies did not demonstrate a higher prevalence of this tumor in Blacks than in Whites (6)(7)(8).…”

Section: Introductionmentioning

confidence: 95%

Prevalence of prostate adenocarcinoma according to race in an university hospital

et al. 2003

View full text Add to dashboard Cite

Objectives: To determine the prevalence of prostate cancer and to assess potential associations between race and prostate adenocarcinoma according to age in patients followed in an outpatient service of general urology in an university hospital.Materials and Methods: Retrospective study of men aged from 40 to 79 years, followed during the period from 1999 to 2001. Patients were classified according to race in White, Mulatto and Black. Those with abnormal digital rectal examination and/or serum level of prostate specific antigen (PSA) > 4.0 ng/ml, underwent a transrectal prostate biopsy.Results: 580 patients with mean age of 60.7 ± 10.0 years were studied, with 116 Whites (20.0%), 276 Mulattos (47.6%) and 188 Blacks (32.4%). There was no significant difference regarding the mean age (p = 0.62), serum level of PSA (p = 0.65) and prevalence of prostate adenocarcinoma between Whites, Mulattos and Blacks (p = 0.36). While studying the association between race classified in 2 groups (Whites versus Mulattos and Blacks) and prostate adenocarcinoma according to age, no association was found when the total group was assessed, neither among those with age above 60 years old. In the group between 40 and 60 years, even though without statistical significance, the estimate of prevalence ratio was 2.2 (CI 95%: 0.52 to 9.0; p = 0.38).Conclusion: Prostate adenocarcinoma was found in 16.6% of the patients aged between 40 and 79 years. We did not find a racial influence in our population.

show abstract

Section: Introductionmentioning

confidence: 95%

Prevalence of prostate adenocarcinoma according to race in an university hospital

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Even though patients with a good prognosis at the start of treatment have been shown to have a longer response duration [11], there remains a need for new methods of predicting outcome. Further investigation of the decline of PSA following androgen deprivation may provide a method for assessing the risk of progression [12].…”

Section: Introductionmentioning

confidence: 99%

Prostate-Specific Antigen Dynamics Predict Risk of Progression in Advanced Prostate Cancer Treated with Bicalutamide plus Castration

Altwein¹,

Schmidt²

2002

Urol Int

View full text Add to dashboard Cite

Objective: The aim of this study was to investigate the prognostic value of prostate-specific antigen (PSA) dynamics in patients treated with combined androgen blockade (CAB). Methods: Patients with locally advanced or metastatic prostate cancer (n = 317) received bicalutamide (50 mg once daily) plus either goserelin acetate or surgical castration for 48 weeks. Cox’s proportional hazard analysis was used to determine whether the decline of PSA following the use of this combination is predictive of a delay in progression. Results: PSA levels at weeks 4 and 12 were statistically significant prognostic markers in predicting disease progression. The PSA rate of change to week 12 was also a statistically significant prognostic marker, although the PSA rate of change at week 4 did not reach statistical significance. These results were statistically less robust than those for PSA levels. Bicalutamide plus castration was well tolerated and effective in advanced prostate cancer. Conclusion: These results suggest that PSA dynamics at weeks 4 and 12 may predict time to progression in advanced prostate cancer treated with CAB.

show abstract

Surgical androgen deprivation therapy in advanced prostate cancer in patients of African descent: comparison of biochemical efficacy of bilateral total and subcapsular orchidectomy

Arogundade¹,

Popoola²,

Ajape³

et al. 2023

Afr H. Sci.

View full text Add to dashboard Cite

Background: Surgical androgen deprivation therapy (ADT) to treat advanced prostate cancer can be achieved either by bilateral total orchidectomy (BTO) or bilateral subcapsular orchidectomy (BSCO). However, biochemical and clinical equivalence between BTO and BSCO among native Africans is undocumented. Objective: To compare the biochemical response (testosterone and prostate specific antigen) in patients who had BTO and BSCO for advanced prostate cancer. Methods: A randomized single- blind study of 64 consenting patients that underwent either BTO or BSCO. Pre- and post-operative PSA and testosterone assays were done serially at intervals and compared between each treatment group. Results: Each treatment group were similar with no statistically significant difference in terms of age (p= 0.449) or degree of tumor differentiation (p =0.714). Neither median testosterone (p= 0.515) nor the mean pre-operative PSA differ between the two groups (p = 0.482). Also, similar trends were noticed post operatively except at the 2nd month when a statistically significant difference was recorded (p = 0.003). Conclusion: The two techniques of orchidectomy were effective in accomplishing androgen deprivation. They produced similar biochemical (testosterone and PSA) response. Keywords: androgen deprivation therapy; subcapsular orchidectomy; total orchidectomy.

show abstract

Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer

Abstract: The PSA determination performed on the 30th postoperative day is important in the evaluation of advanced prostate cancer prognosis.

Cited by 3 publications

References 18 publications

Prevalence of prostate adenocarcinoma according to race in an university hospital

Prevalence of prostate adenocarcinoma according to race in an university hospital

Prostate-Specific Antigen Dynamics Predict Risk of Progression in Advanced Prostate Cancer Treated with Bicalutamide plus Castration

Surgical androgen deprivation therapy in advanced prostate cancer in patients of African descent: comparison of biochemical efficacy of bilateral total and subcapsular orchidectomy

Contact Info

Product

Resources

About